Publicaciones (31) Publicaciones en las que ha participado algún/a investigador/a

2024

  1. A mouse model to assess immunotherapy-related colitis

    Methods in Cell Biology (Academic Press Inc.)

  2. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809

  3. An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)

    International Journal of Gynecological Cancer, Vol. 34, Núm. 6, pp. 942-945

  4. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)

    Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186

  5. Cardiophrenic lymph node dissection in ovarian cancer patients

    Ovarian Cancer: The "Gynaecological Challenge? From Diagnostic Work-Up to Cytoreduction and Chemotherapy (Nova Science Publishers, Inc.), pp. 155-160

  6. Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer

    European Journal of Cancer, Vol. 202

  7. Consensus on surgical technique for sentinel lymph node dissection in cervical cancer

    International Journal of Gynecological Cancer, Vol. 34, Núm. 4, pp. 504-509

  8. Current Management and Future Perspectives in Metastatic HER2-Positive Breast Cancer

    Seminars in Oncology Nursing, Vol. 40, Núm. 1

  9. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  10. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

    Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58

  11. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 187, pp. 128-138

  12. Elevated expression of complement factor I in lung cancer cells associates with shorter survival–Potentially via non-canonical mechanism

    Translational Research, Vol. 269, pp. 1-13

  13. Fasting and fasting-mimicking conditions in the cancer immunotherapy era

    Journal of Physiology and Biochemistry

  14. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 184, pp. 168-177

  15. High pre-Delta and early-Omicron SARS-CoV-2 seroprevalence detected in dried blood samples from Kinshasa (D.R. Congo)

    Journal of Medical Virology, Vol. 96, Núm. 3

  16. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study

    Gynecologic Oncology, Vol. 186, pp. 182-190

  17. Management challenges in low-grade serous ovarian cancer with a BRCA mutation

    International Journal of Gynecological Cancer, Vol. 34, Núm. 4, pp. 631-636

  18. Ovarian cancer during fertility follow-up

    International Journal of Gynecological Cancer

  19. Prevalence and Distribution of MUTYH Pathogenic Variants, Is There a Relation with an Increased Risk of Breast Cancer?

    Cancers, Vol. 16, Núm. 2

  20. Primary and secondary postpartum haemorrhage: a review for a rationale endovascular approach

    CVIR ENDOVASCULAR, Vol. 7, Núm. 1